Protocols

Celgene grabs more space in Cambridge; Karolinska Dev gets new CEO

→ Fast-growing Celgene is expanding its footprint in Cambridge, MA, reports the Boston Business Journal, subletting 40,000 square feet of space that had been emptied after Amgen moved staff to a new facility on Kendall Square.

Novartis has long been discontented with its big Alcon unit, reportedly considering an exit at the tight price. Now Bloomberg reports that the pharma giant engaged Bank of America to step in to “review options.”

Karolinska Development announced that Chairman Bo Jesper Hansen and CEO Jim Van heusden have decided to step down. Viktor Drvota has been promoted to CEO.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 30,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

RAPS Convergence 2018

Technical Operations Manager
Molecular Templates Austin, TX
Senior Director, Global Commercial Strategy, Rare Disease
Govig BioPharma/Aeglea BioTherapeutics Austin, TX
Senior Manager, Sales & Client Development
Aldevron Boston or San Francisco
Scientist, Cellular Immunology
Codiak BioSciences Cambridge, MA
Director of Quality Assurance
Aldevron Fargo, ND
Principal Scientist, Immuno-Oncology (Inflammation)
Codiak BioSciences Cambridge, MA

Visit Endpoints Careers ->